4.8 Review

Roles for Innate Immunity in Combination Immunotherapies

Journal

CANCER RESEARCH
Volume 77, Issue 19, Pages 5215-5221

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-17-1340

Keywords

-

Categories

Funding

  1. Koch Institute from the National Cancer Institute [P30-CA14051]
  2. Ragon Institute MGH, MIT, and Harvard
  3. Koch Institute for Integrative Cancer Research
  4. Dana Farber/Harvard Cancer Center (DF/HCC)
  5. Mayo Clinic-Koch Institute Collaboration
  6. Marble Center for Cancer Nanomedicine
  7. NIH [EB022433, CA172164, CA174795, CA206218]
  8. Stand Up To Cancer - Breast Cancer Research Foundation Convergence Team [SU2C-BCRF 2015-001]

Ask authors/readers for more resources

Immunity to infectious agents involves a coordinated response of innate and adaptive immune cells working in concert, with many feed-forward and regulatory interactions between both arms of the immune system. In contrast, many therapeutic strategies to augment immunity against tumors have focused predominantly on stimulation of adaptive immunity. However, a growing appreciation of the potential contributions of innate immune effectors to antitumor immunity, especially in the context of combination immunotherapy, is leading to novel strategies to elicit a more integrated immune response against cancer. Here we review antitumor activities of innate immune cells, mechanisms of their synergy with adaptive immune responses against tumors, and discuss recent studies highlighting the potential of combination therapies recruiting both innate and adaptive immune effectors to eradicate established tumors. (C) 2017 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available